ProQR's QR-313 an Orphan Drug in Europe for DEB; shares up 2% [Seeking Alpha]
ProQR Therapeutics N.V. - Ordinary Shares (PRQR)
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
proqr.com
Company Research
Source: Seeking Alpha
ProQR's QR-313 an Orphan Drug in Europe for DEB; shares up 2%The European Medicines Agency (EMA) designates ProQR Therapeutics' (PRQR+1.5%) QR-313 an Orphan Drug for the treatment ofdystrophic epidermolysis bullosa (DEB), an inherited disorder characterized by skin blisters.QR-313 is an RNA-based oligonucleotide designed to address the underlying genetic cause of DEB.Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.The FDA designated QR-313 an Orphan Drug for DEB several months ago.See all stocks on the move »
Show less
Read more
Impact Snapshot
Event Time:
PRQR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRQR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRQR alerts
High impacting ProQR Therapeutics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRQR
News
- ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024GlobeNewswire
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingGlobeNewswire
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio [Yahoo! Finance]Yahoo! Finance
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioGlobeNewswire
- ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc. from $1.80 to $2.00. They now have a "buy" rating on the stock.MarketBeat
PRQR
Earnings
- 11/7/23 - Miss
PRQR
Sec Filings
- 4/23/24 - Form 6-K
- 4/19/24 - Form 6-K
- 3/13/24 - Form 20-F
- PRQR's page on the SEC website